Table 3.
Overview of response rates and downstaging success rates with 90Y-RE in patients with metastatic disease
| Author | Year | N | RECIST (%) | WHO (%) | EASL (%) | Downstaging success rate | Median time to response/downstaging | Resection | LTX | |||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CR | PR | CR | PR | CR | PR | % | Months (range) | %d | %d | |||
| Whitney [59] | 2011 | 44 | – | –a | – | – | – | – | 9 | – | 9 | 0 |
| Vouche [58] | 2013 | 8 | – | – | – | – | – | – | 13 | – | 13 | 0 |
| Moirb [52] | 2015 | 44 | 0 | 10 | – | – | – | – | 16 | 4.0 (2.3–10.9) | 16 | 0 |
| Justinger [46] | 2015 | 13 | – | – | – | – | – | – | 85 | 1.8 (1.3–4.9) | 85 | 0 |
| Henryc [44] | 2015 | 9 | – | – | – | – | – | – | 29 | 3.8 (1.8–8.3) | 100 | 0 |
aAll surgical candidates (n = 4) had PR according to RECIST
bMixed population (CRLM 14, 8 HCC, 5 NET, 4 other); 4/14 CRLM underwent surgery
cRetrospective series with a mixed population of secondary liver malignancies (CRLM 4, 3 NET, 1 gastrointestinal stromal tumor and 1 cervical carcinoma)
dPercentage of the total population